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IntroductIon 
Since 1996, the prognosis of people living with immunodeficiency virus (HIV) and acquired 
immunodeficiency syndrome (AIDS) has improved significantly, due to highly active 
antiretroviral therapies (HAART) based on a combination of 3-4 anti-HIV drugs; the use of 
these drugs can achieve a durable suppression of HIV viraemia, turning HIV infection into a 
chronic illness. The three first licensed classes of antiretroviral agents are nucleoside reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 
protease inhibitors (PIs). Until recently, treatment options for individuals developing resistance 
to these drugs have been limited, but new drugs in existing classes (second generation 
NNRTIs and novel PIs) and novel classes of drugs (integrase inhibitors, CCR5 antagonists 
and fusion inhibitors) have become clinically available.
IndIcatIons and dosIng 
Maraviroc (MVR) is the first antiretroviral agent belonging to the new pharmacological class 
of CCR5-antagonists to be approved by the US Food and Drug Administration. MVR, in 
combination with other antiretroviral products, is indicated for adult patients infected with only 
CCR5-tropic HIV-1 virus strains resistant to multiple antiretroviral agents, and in presence of 
demonstrated active viral replication. This drug is available in film-coated tablets containing 
150 or 300 mg of MVR; the recommended dose is of 150, 300 or 600 mg (depending on co-
administered antiretroviral therapy and potential drug-drug interactions) twice daily. Tropism 
testing is required before initiation of treatment. MVR is currently included by AIFA (Agenzia 
Italiana del Farmaco) in a drug efficacy and safety monitoring program.
PharmacokInetIcs
Pharmacokinetics of MVR is not influenced by gender, race or weight; age appears to 
influence MVR clearance, but the studied range (18-54 y) is very limited and insufficient data is 
available for the elderly. MVR can be taken with or without food, although a plentiful breakfast 
can considerably reduce its bioavailability. Dose adjustment is required in patients with renal 
impairment who are taking CYP3A4 inhibitors, and caution is needed in case of renal, hepatic 
or cardiac function problems.
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absorption
Bioavailability cmax tmax Binding to plasma proteins
23% at a 150 mg dose, 
33% at a 300 mg dose
638 ng/ml
0.5 to 4 h  
(mean 2-3 h)
73-78% (albumin and alpha-1 
acid glycoprotein)
metabolism and distribution
Volume of distribution metabolism enzimes metabolites
194 l Hepatic CYP3A4 Inactive
elimination
clearance Plasma terminal half-life elimination Interactions 
44 l/h 14-18 h
76.4% feces, 
19.6% in urine 
(over 168 h)
CYP3A4 and/or P-glycoprotein 
inducers or inhibitors; 
St. John's wort.
table I
Absorption, distribution, metabolism and elimination of maraviroc after oral administration
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PharmacodynamIcs
HIV-1 strains can be categorized by their co-receptor tropism, i.e. their ability to use CCR5 
(CCR5-tropic), CXCR4 (CXCR4-tropic), or both (dual-tropic) human chemokine receptors as co-
receptors for entry into susceptible cells. MVR is a specific, slowly reversible, noncompetitive, 
small-molecule CCR5-antagonist, which acts by binding to the transmembrane region of this 
receptor, and stabilizing a conformation not recognized by the virus, which cannot enter host 
CD4+ cells. Resistance to MVR can occur by HIV mutagenesis, and was seen in both in vivo 
and in vitro samples.
effIcacy and safety
MVR has demonstrated in vitro activity against a wide range of CCR5-tropic clinical isolates, 
including those resistant to the four currently existing classes of antiretroviral agents. Results 
of phase III clinical trials (MOTIVATE 1 and 2) demonstrate that this drug, in combination with 
optimized background therapy (OBT: 3-6 other antiretroviral products, excluding low-dose 
ritonavir), is superior to OBT alone in treatment-experienced patients infected with CCR5-
tropic HIV-1, causing a significantly greater reduction in viral load and an increase in CD4+ 
cell count. In treatment-naïve patients, MVR formally failed to prove its non-inferiority to a 
standard regimen consisting of AZT/3TC + efavirenz after 48 weeks. 
MVR appeared relatively well tolerated, with no particular concerns; in fact, no significant 
increases in cardiovascular events, hepatotoxicity, infections or malignancies have been 
reported. Several post-marketing, ongoing studies will assess the long-term safety on immune 
and liver function, malignancy, cardiac events, and risks associated with changes in tropism.
economIc eValuatIons
Currently, HIV treatment in Italy is based on HAART therapies, which consists in the mix of 
three or more antiretroviral agents. Possible combinations are made up of 2 NRTIs + 1 NNRTI, 
2 NRTIs + 1/2 PIs, or 3 NRTIs. The daily cost of this therapy ranges from 15 to 28 €/die, with 
a mean of 22 €/die, for a monthly cost of about 650 €. This evaluation is based on dosages 
reported in the SPCs (Summary of Products Characteristics) and ex-factory prices.  
As no alternative strategy can be identified, since MVR is to be added to standard OBT therapy, 
monthly pharmaceutical costs for this treatment are simply presented in Table III. 
Tropism testing is required before the initiation of MVR treatment; TrofileTM HIV Entry Tropism 
Assay (Monogram), the test used in clinical trials, is delivered free of charge to hospitals by 
the drug manufacturer.
 study design efficacy (at week 24) safety 
MOTIVATE 1 Double-blind, randomized study 
comparing MVR + OBT qd vs MVR + 
OBT bid vs placebo + OBT (2:2:1) in 
601 pts with CCR5-tropic HIV1
hIV-rna change from baseline (log10 cps/ml):
MVR qd: -1.88
MVR bid: -1.96
Placebo: -0.99
Vl < 400 cps/ml (%):
MVR qd: 55.1
MVR bid: 61.0
Placebo: 27.8
Vl < 50 cps/ml (%):
MVR qd: 44.0
MVR bid: 45.3
Placebo: 23.0
Treatment-related AEs 
occurring at a higher 
incidence than placebo 
(2% or 2-fold): 
abdominal pain, 
dyspepsia, muscle 
spams, myalgia, taste 
disturbance, cough and 
cutaneous rash.
MOTIVATE 2 Double-blind, randomized study 
comparing MVR + OBT qd vs MVR + 
OBT bid vs placebo + OBT (2:2:1) in 
475 pts with CCR5-tropic HIV1
table II 
Summary of main studies investigating efficacy and safety of maraviroc in HIV-1 patients. Dosage of maraviroc was 300 mg, or 150 mg for 
patient receiving protease inhibitors
 AE = adverse events; CK = creatine kinase; cps = copies; MVR = maraviroc; OBT = optimized background therapy; pts = patients; 
VL = viral load 
Packages 
cost/package (€) monthly cost (€)
Public ex-factory < >
150/300 mg, 60 cpr 1,340.55 812.25 812.25 3,249.00 
table III
Monthly pharmaceutical costs of maraviroc therapy in HIV treatment (Informatore Farmaceutico 2008)
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Name of the Medicinal Product Celsentri
Marketing Authorisation Holder Pfizer
Active Substance Maraviroc
Pharmaco-therapeutic Group Other antivirals
ATC Code J05AX09
Date of issue of Marketing Authorisation valid 
throughout the European Union 
18 September 2007
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